IL2

Chr 4

interleukin 2

Also known as: IL-2, TCGF, lymphokine

NCBI Gene: 3558ENSG00000109471UniProt: P60568

This gene is a member of the interleukin 2 (IL2) cytokine subfamily which includes IL4, IL7, IL9, IL15, IL21, erythropoietin, and thrombopoietin. The protein encoded by this gene is a secreted cytokine produced by activated CD4+ and CD8+ T lymphocytes, that is important for the proliferation of T and B lymphocytes. The receptor of this cytokine (IL2R) is a heterotrimeric protein complex whose gamma chain is also shared by IL4 and IL7. The expression of this gene in mature thymocytes is monoallelic, which represents an unusual regulatory mode for controlling the precise expression of a single gene. The targeted disruption of a similar gene in mice leads to ulcerative colitis-like disease, which suggests an essential role of this gene in the immune response to antigenic stimuli. [provided by RefSeq, Sep 2020]

GeneReviewsResearchGenerating clinical summary…

Clinical highlights

Interpreting a novel variant
This gene is strongly intolerant of loss-of-function variation in the population, so LoF variants warrant close attention. No curated mechanism annotation is available — see the mechanism card for the computational prediction and its caveats.Based on population constraint only.
12
Active trials
263
Pubs (1 yr)
—
P/LP submissions
—
P/LP missense
0.81
LOEUF
GOF
Mechanism· predicted
📖
GeneReview available — IL2
Authoritative clinical overview · Recommended first read
Open GeneReview ↗
Some data sources returned errors (1)

omim: Error: OMIM fetch failed: 429

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

gnomAD
Tolerant — LoF & missense variants common in population
LoF Constraint?
0.81LOEUF
pLI 0.480
Z-score 1.86
OE 0.17 (0.06–0.81)
Tolerant

Typical tolerance to LoF variation

Missense Constraint?
1.43Z-score
OE missense 0.53 (0.41–0.69)
38 obs / 72.2 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios?
LoF OE?0.17 (0.06–0.81)
0≤0.351.4
Missense OE?0.53 (0.41–0.69)
0≤0.61.4
Synonymous OE?1.28
0≤1.21.6
LoF obs/exp: 1 / 5.9Missense obs/exp: 38 / 72.2Syn Z: -1.14

ClinVar Variant Classifications

0 submitted variants in ClinVar

ClinVar

Protein Context — Lollipop Plot

IL2 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

ClinicalTrials.gov
ANCA Associated Vasculitis (AAV)

The Safety, Efficacy, and Cellular Metabolic Kinetics of CT1192 in Treating Patients With Anti Neutrophil Cytoplasmic Antibody Associated Vasculitis

NOT YET RECRUITING
NCT07033299Phase PHASE1Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyStarted 2025-07-01
CAR-T Therapy
SARS CoV 2 InfectionSARS CoV 2 Vaccination

COVID-19 Transmission and Morbidity in Malawi

RECRUITING
NCT05973084Boston UniversityStarted 2023-01-17
Rare Malignant NeoplasmAdvanced Solid TumorsMetastatic Solid Tumors

Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)

NOT YET RECRUITING
NCT07307053Phase PHASE1, PHASE2Cancer Institute and Hospital, Chinese Academy of Medical SciencesStarted 2026-01-01
BL-B01D1VSV injectionCVL006
Stress Disorders, Post-Traumatic

Role of Sympathetic Overactivity and Angiotensin II in PTSD and CV

RECRUITING
NCT02560805Phase PHASE2Emory UniversityStarted 2015-10
MicroneurographyCombat virtual reality video clipHandgrip Exercise
Overweight and ObesityLupus Erythematosus

Methyl-donor Nutrient Supplementation and Methylation Profile in Lupus Patients With Obesity

ENROLLING BY INVITATION
NCT05097365Phase NAUniversity of Sao PauloStarted 2022-01-01
Vitamin B12 + folic acid supplementationPlacebo supplementation
Advanced Pancreatic Cancers

A Clinical Study of CHT102 in MSLN-Positive Advanced Pancreatic Cancer

RECRUITING
NCT06760364Phase PHASE1Tianjin Medical University Cancer Institute and HospitalStarted 2024-12-25
CHT102
T-cell Lymphoma

A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma

ACTIVE NOT RECRUITING
NCT03952078Phase PHASE1Corvus Pharmaceuticals, Inc.Started 2019-05-03
CPI-818
Prostate Cancer

Pembro With Radiation With or Without Olaparib

RECRUITING
NCT05568550Phase PHASE2Zin W MyintStarted 2023-07-27
PembrolizumabOlaparibAndrogen Deprivation Therapy
Non-Allergic Rhinitis With Eosinophilia Syndrome

Efficacy and Safety of Stapokibart in Non-Allergic Rhinitis With Eosinophilia Syndrome

NOT YET RECRUITING
NCT07240376Phase NAHuazhong University of Science and TechnologyStarted 2025-11-25
Stapokibart (CM310)Placebo
DysferlinopathyMiyoshi MyopathyLGMDR2

Clinical, Immunological, Morphological and Genetic Characteristics of Patients With Dysferlinopathy (LGMD R2) in the RF

ENROLLING BY INVITATION
NCT04824040Artgen BiotechStarted 2020-01-15
Fibromyalgia (FM)tDCSDuloxetine

Home-based Transcranial Direct Current Stimulation (tDCS) Compared to Duloxetine: Non-inferiority Clinical Trial (FIBROSTIM)

RECRUITING
NCT07203339Phase NAHospital de Clinicas de Porto AlegreStarted 2025-09-30
Transcranial direct current stimulation (tDCS) plus placebo.Duloxetine (60 mg) once dailyHome-based transcranial direct current stimulation
Non Hodgkin's Lymphoma

TRAC and Power3 (SPPL3) Genes Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-NHL

RECRUITING
NCT06014073Phase PHASE1, PHASE2Chinese PLA General HospitalStarted 2023-09-06
TRAC and Power3 (SPPL3) Genes Knock-out Allogeneic CD19-targeting CAR-T cell (ATHENA CAR-T)FludarabineCyclophosphamide

External Resources

Links to major genomics databases and tools

Franklin by Genoox
AI-powered variant curation and clinical analysis
DECIPHER
Genomic variants and phenotypes in rare disease patients